Genotyping non-small cell lung cancer (NSCLC) in Latin America (LATAM).

e21155 Background: Epidermal Growth Factor Receptor (EGFR) and K-ras are key pathways in NSCLC; mutations in these genes determine a subgroup of patients with different prognosis and therapeutic approach. The frequency of mutations varies between different ethnic groups; so far, EGFR and K-ras mutations have not been described in the LATAM population. Methods: EGFR and K-ras mutation analyses were performed using DNA sequencing or Therascreen PCR-kit. Results: EGFR mutations were evaluable in 832 patients (Mexico 295; Colombia 228; Peru 185; Argentina 124). 35.8% patients had EGFR mutations, 47.9% with E19 deletion; 48.3% with the in-frame L858R mutation. 19.8% patients had K-ras mutation (303 patients evaluated). Conclusions: LATAM NSCLC patients were more likely to harbor activating EGFR mutations and K-ras mutations were less frequent. Patient characteristics. Variable Argentina Colombia Mexico Peru Total Number of patients 124 228 295 185 832 Mean age (±SD) 62.0 (11) 59.0 (13) 60.3 (13) 62.2 (11.1) 60...